16 February 2015

Director's Dealing

RNS Number : 9407E
Verona Pharma PLC
16 February 2015
 

Verona Pharma plc

("Verona Pharma" or the "Company")

 

Director's Dealing

 

 

16 February 2015, Cardiff- Verona Pharma plc (AIM: VRP) received notification on 13 February 2015 that on that date Dr. Jan-Anders Karlsson, CEO of the Company, purchased 1,025,909 ordinary shares of 0.1p each in the Company ("Ordinary Shares") at a price of 2 pence per share.

Following the acquisition, Dr. Karlsson will have an interest in the Company of 2,735,000 Ordinary Shares, representing 0.27% of the Company's issued share capital. 

 

 

 

-Ends-

 

 

For further information please contact:

 

Verona Pharma plc

Tel: +44 (0) 20 3283 4200

Jan-Anders Karlsson, CEO

N+1 Singer

Tel: +44 (0)20 7496 3000

Aubrey Powell / Jen Boorer

FTI Consulting

Tel: +44 (0)20 3727 1000

Julia Phillips / Simon Conway

 

 

Notes to Editors

 

About Verona Pharma plc

Verona Pharma plc is a UK-based clinical stage biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD, asthma and cystic fibrosis. Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase II trials as a nebulised treatment for acute exacerbations of COPD in the hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both bronchodilator and anti-inflammatory effects, which are essential to the improvement of patients with COPD and asthma. Verona Pharma is also building a broader franchise around RPL554 to maximise its value, both to patients and to investors. This includes the very significant markets for COPD and asthma maintenance therapy. The Company is also exploring the potential of the drug in different diseases, such as cystic fibrosis, where it is in pre-clinical testing. 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSDELFFELFXBBV

For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / James White
Tel: +44 (0)20 7496 3000

 

 

FTI Consulting
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us